Immunoglobulin E specific for Rumex acetosella pollen allergens (Rum a-specific IgE)

Immunoglobulin E (IgE) antibodies specific for Rumex acetosella (sheep sorrel) pollen epitopes are the primary mediators of Type I hypersensitivity reactions to this weed pollen. These antibodies are produced by B cells following sensitization to specific allergenic proteins, most notably Rum a 1, which is a defensin-like protein identified as the major allergen in sheep sorrel (Source: WHO/IUIS Allergen Nomenclature). Once synthesized, these IgE molecules circulate in the blood and bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent inhalation or contact with Rumex acetosella pollen, the allergens cross-link the receptor-bound IgE, triggering the immediate degranulation of these effector cells and the release of inflammatory mediators such as histamine, leukotrienes, and cytokines (Source: Janeway's Immunobiology). This physiological response manifests clinically as allergic rhinitis, conjunctivitis, and in some cases, exacerbation of asthma. Therapeutic strategies targeting these specific IgE antibodies include the use of omalizumab, a monoclonal antibody that neutralizes free IgE regardless of its allergen specificity, and allergen-specific immunotherapy (AIT), which aims to desensitize the patient by modifying the underlying immune response to the pollen (Source: PubMed PMID: 26903167). Monitoring the levels of Rumex-specific IgE in the serum is a critical diagnostic step in identifying patients who will benefit from these targeted interventions.

Other names

Sheep sorrel-specific IgEAnti-Rumex acetosella IgEIgE against Rum a 1Rumex acetosella-specific IgE

Omalizumab acts as an anti-IgE antibody that binds to the Fc region of circulating IgE, specifically the Cε3 domain, preventing it from binding to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (Source: FDA, PubMed PMC7016598). This sequestration inhibits the allergic cascade before it begins. Allergen-specific immunotherapy (AIT) using Rumex acetosella pollen extract works by exposing the immune system to gradually increasing doses of the allergen to induce peripheral T-cell tolerance, increase the production of regulatory T cells (Tregs), and promote a shift from a Th2 to a Th1 immune response, alongside the production of 'blocking' IgG4 antibodies (Source: EAACI, PubMed PMID: 29206310).